Bio­gen lays out a plan to “stream­line” ops, add $400M to fund neu­ro­sciences R&D, new deals

Bio­gen saw its share price $BI­IB pop up more than 5% Tues­day morn­ing as the com­pa­ny re­port­ed sharply high­er rev­enue for Spin­raza, in­di­cat­ing that they …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.